<p>Naloxone is an important opioid antagonist often used for the rapid reversal of opioid-induced respiratory depression and life-threatening opioid overdose. It has become more essential globally because of the rising opioid crisis and its application in emergency medicine as well as community harm-reduction efforts. This review offers an in-depth introduction to naloxone, encompassing the history, synthetic protocols, and molecular mechanism of action as a competitive antagonist primarily at µ-opioid receptors. The structure-activity relationship (SAR) features of naloxone that influence receptor affinity and antagonistic activity are discussed. Further, the molecular docking demonstrated the naloxone-receptor interactions at the binding site. The pharmacokinetic and pharmacodynamic profile of naloxone, which includes a rapid onset and short duration of action, is critically examined in relation to clinical outcomes. Additionally, the discussion covers emerging therapeutic roles, current clinical applications, limitations, and adverse effects, including withdrawal precipitation and opioid renarcotization. A comparative examination with similar opioid antagonists, i.e., naltrexone and nalmefene, highlighted the disparities in duration, clinical utility, and bioavailability. Finally, the future perspectives to develop the next-generation opioid antagonists are provided, focusing on enhanced formulations, longer-acting analogs, and advanced computational approaches.</p>